OTC Stock Market News Today
Investing News Show
The October 21, 2014 Money Info OTC Stock Market News Today show featured live interviews with:
Jason Paltrowitz,
Managing Director of Business Development
for
OTC Markets Group
Listen to Part 1 replay of the Show with Jason Paltrowitz interview:
OTC Markets Stock News
See website: http://www.otcmarkets.com
and
Rachel Levine Vice President, Investor Relations for
Cleveland BioLabs, Inc.
(NASDAQ Stock Symbol: CBLI)
Corporate Site: cbiolabs.com
Investors Conference Call Transcript — Click Here
Financials News – Click Here
Listen to Part 2 replay of the Show with
Rachel Levine of Cleveland BioLabs, Inc.
Medical Stocks To Buy CBLI
Money Info Show Airs
10 AM to 11 AM EDT
Every Tuesday
LISTEN LIVE
Use this Link To Watch The Show:
www.princetonresearch.com/money-info-live.htm
Be On The Air With Us
Call In Your Questions
888-792-1590
Jason Paltrowitz, managing director of business development for the OTC Markets Group
See website: http://www.otcmarkets.com
See Facebook Page: https://www.facebook.com/OTCMarkets
Jason Paltrowitz is the Managing Director and Global Head of Business Development at OTC Markets Group. Mr. Paltrowitz joined the company on October 2013 after serving more than two years as a Managing Director and Segment Head at JP Morgan Chase & Co. where he managed the custody, clearing and collateral management business in the Corporate and Investment Bank division.
Prior to that, he held several senior management positions at Bank of New York Mellon Corp. Mr. Paltrowitz was also a member of the board of directors at OTC Markets Group from 2008 to 2011 and helped launch the OTCQX marketplace PAL offering for ADR issuers at Bank of New York Mellon.
OTC MARKETS
Three Tiered Marketplaces
The OTC Markets are Open, Transparent and Connected financial marketplaces that provide investors with the information necessary to intelligently analyze, value and trade 10,000 U.S. and global securities through the broker of their choice.
To create clarity in the investment process, we organize these securities into three tiered marketplaces – OTCQX, OTCQB and OTC Pink – based on the quality and quantity of information the companies make available.
Figures are for October 21, 2014 9:30 EDT
The Best Marketplace
The OTCQX® best marketplace is for established investor-focused U.S. and global companies. To qualify for the OTCQX marketplace, companies must meet high financial standards, demonstrate compliance with U.S. securities laws, be current in their disclosure, and be sponsored by a professional third-party advisor. The companies found on OTCQX are distinguished by the integrity of their operations and diligence with which they convey their qualifications.
The Venture Marketplace
The OTCQB® venture marketplace is for entrepreneurial and development stage U.S. and international companies that are unable to qualify for OTCQX. To be eligible, companies must be current in their reporting and undergo an annual verification and management certification process. These standards provide a strong baseline of transparency, as well as the technology and regulation to improve the information and trading experience for investors. However, since there are no minimum financial standards other than a $0.01 bid test, companies will vary in their financial strength.
The Open Marketplace
The OTC Pink® marketplace offers trading in a wide spectrum of equity securities through any broker. This marketplace is for all types of companies that are there by reasons of default, distress or design, which is why they are further sub-categorized by the levels of information that they provide.
Listen to the second hour of the show for:
Rachel Levine Vice President, Investor Relations for
Cleveland BioLabs, Inc.
(NASDAQ Stock Symbol: CBLI)
Corporate Site: cbiolabs.com
Investors Conference Call Transcript — Click Here
Financials News – Click Here
Radiation Exposure Treatment Medical Stocks To Buy
Cleveland BioLabs (CBLI) Announces
Green Light to Submit
Pre-Emergency Use Authorization Application for Entolimod
Buffalo, NY – September 3, 2014 – Cleveland BioLabs, Inc. (NASDAQ:CBLI) today announced that the minutes from its meeting with the U.S. Food and Drug Administration (FDA) in July confirmed that the Company’s existing efficacy and safety data and animal-to-human dose conversion are sufficient to proceed with a pre-Emergency Use Authorization (pre-EUA) submission for entolimod for reducing the risk of death following exposure to potentially lethal irradiation occurring as the result of a radiation disaster.
See more at:
http://www.princetonresearch.com/medical-stock-news-cbli/
Radiation Exposure Treatment Drugs
Stock News
Just imagine the catastrophe if radioactive material falls into the wrong hands. The Russians have invested heavily in this. CBLI is involved in the development of Entolimod, which is being developed as radiation countermeasure and a potential cancer treatment, and Curaxin CBL0137, the lead oncology product candidate.
The company conducts business in the United States and in the Russian Federation through our three operating subsidiaries, Incuron, LLC, BioLabs 612, LLC and Panacela Labs, Inc. The company maintains strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, and the Children’s Cancer Institute Australia.
To learn more about Cleveland BioLabs, Inc., please visit the Company’s website at http://www.cbiolabs.com.
Cleveland BioLabs (CBLI) Announces
Green Light to Submit
Pre-Emergency Use Authorization Application for Entolimod
Stock Market News Today Show
Money Info
The Princeton Research Money Info show features where to invest now, stock market, business, economy and financial investment news.
Money Info is hosted by Mike King and Charles Moskowitz.